Our partner is leveraging targeted protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases. They integrate their foundational degrader portfolio, extensive internal drug hunting expertise, and their lead partner’s proprietary deep learning platform to advance novel protein degraders across a range of therapeutic areas.

This critical hire brought extensive experience in ADME and DMPK to program teams. They were responsible for comprehensive DMPK support, including design, execution, and interpretation of all DMPK studies, PK/PD modelling, collaboration with colleagues on translational studies of all discovery and development programs. They also helped write and review relevant sections of regulatory documents, as well as built and mentored a team.